-
Je něco špatně v tomto záznamu ?
Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer
ML. Piccinelli, S. Luzzago, G. Marvaso, E. Laukhtina, N. Miura, VM. Schuettfort, K. Mori, A. Colombo, M. Ferro, FA. Mistretta, N. Fusco, G. Petralia, BA. Jereczek-Fossa, SF. Shariat, PI. Karakiewicz, O. de Cobelli, G. Musi
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- biopsie MeSH
- lidé MeSH
- nádory prostaty * diagnóza patologie MeSH
- pozorné vyčkávání MeSH
- prostatická intraepiteliální neoplazie * MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: To test any-cause discontinuation and ISUP GG upgrading rates during Active Surveillance (AS) in patients that underwent previous negative biopsies (PNBs) before prostate cancer (PCa) diagnosis vs. biopsy naive patients. METHODS: Retrospective analysis of 961 AS patients (2008-2020). Three definitions of PNBs were used: (1) PNBs status (biopsy naïve vs. PNBs); (2) number of PNBs (0 vs. 1 vs. ≥ 2); (3) histology at last PNB (no vs. negative vs. HGPIN/ASAP). Kaplan-Meier plots and multivariable Cox models tested any-cause and ISUP GG upgrading discontinuation rates. RESULTS: Overall, 760 (79.1%) vs. 201 (20.9%) patients were biopsy naïve vs. PNBs. Specifically, 760 (79.1%) vs. 138 (14.4%) vs. 63 (6.5%) patients had 0 vs. 1 vs. ≥ 2 PNBs. Last, 760 (79.1%) vs. 134 (13.9%) vs. 67 (7%) patients had no vs. negative PNB vs. HGPIN/ASAP. PNBs were not associated with any-cause discontinuation rates. Conversely, PNBs were associated with lower rates of ISUP GG upgrading: (1) PNBs vs. biopsy naïve (HR:0.6, p = 0.04); (2) 1 vs. 0 PNBs (HR:0.6, p = 0.1) and 2 vs. 0 PNBs, (HR:0.5, p = 0.1); (3) negative PNB vs. biopsy naïve (HR:0.7, p = 0.3) and HGPIN/ASAP vs. biopsy naïve (HR:0.4, p = 0.04). However, last PNB ≤ 18 months (HR:0.4, p = 0.02), but not last PNB > 18 months (HR:0.8, p = 0.5) were associated with lower rates of ISUP GG upgrading. CONCLUSION: PNBs status is associated with lower rates of ISUP GG upgrading during AS for PCa. The number of PNBs and time from last PNB to PCa diagnosis (≤ 18 months) appear also to be critical for patient selection.
Department of Oncology and Haemato Oncology Università Degli Studi Di Milano 20122 Milan Italy
Department of Pathology IEO European Institute of Oncology IRCCS Via Ripamonti 435 Milan Italy
Department of Radiotherapy IEO European Institute of Oncology IRCCS Via Ripamonti 435 Milan Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Ehime University Graduate School of Medicine Ehime Japan
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Radiology IEO European Institute of Oncology IRCCS Via Ripamonti 435 Milan Italy
European Association of Urology Research Foundation Arnhem Netherlands
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018279
- 003
- CZ-PrNML
- 005
- 20220804134654.0
- 007
- ta
- 008
- 220720s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-022-03983-8 $2 doi
- 035 __
- $a (PubMed)35347414
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Piccinelli, Mattia Luca $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy. mattiapiccinelli@gmail.com $u Università degli Studi di Milano, Milan, Italy. mattiapiccinelli@gmail.com $1 https://orcid.org/0000000303373331
- 245 10
- $a Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer / $c ML. Piccinelli, S. Luzzago, G. Marvaso, E. Laukhtina, N. Miura, VM. Schuettfort, K. Mori, A. Colombo, M. Ferro, FA. Mistretta, N. Fusco, G. Petralia, BA. Jereczek-Fossa, SF. Shariat, PI. Karakiewicz, O. de Cobelli, G. Musi
- 520 9_
- $a PURPOSE: To test any-cause discontinuation and ISUP GG upgrading rates during Active Surveillance (AS) in patients that underwent previous negative biopsies (PNBs) before prostate cancer (PCa) diagnosis vs. biopsy naive patients. METHODS: Retrospective analysis of 961 AS patients (2008-2020). Three definitions of PNBs were used: (1) PNBs status (biopsy naïve vs. PNBs); (2) number of PNBs (0 vs. 1 vs. ≥ 2); (3) histology at last PNB (no vs. negative vs. HGPIN/ASAP). Kaplan-Meier plots and multivariable Cox models tested any-cause and ISUP GG upgrading discontinuation rates. RESULTS: Overall, 760 (79.1%) vs. 201 (20.9%) patients were biopsy naïve vs. PNBs. Specifically, 760 (79.1%) vs. 138 (14.4%) vs. 63 (6.5%) patients had 0 vs. 1 vs. ≥ 2 PNBs. Last, 760 (79.1%) vs. 134 (13.9%) vs. 67 (7%) patients had no vs. negative PNB vs. HGPIN/ASAP. PNBs were not associated with any-cause discontinuation rates. Conversely, PNBs were associated with lower rates of ISUP GG upgrading: (1) PNBs vs. biopsy naïve (HR:0.6, p = 0.04); (2) 1 vs. 0 PNBs (HR:0.6, p = 0.1) and 2 vs. 0 PNBs, (HR:0.5, p = 0.1); (3) negative PNB vs. biopsy naïve (HR:0.7, p = 0.3) and HGPIN/ASAP vs. biopsy naïve (HR:0.4, p = 0.04). However, last PNB ≤ 18 months (HR:0.4, p = 0.02), but not last PNB > 18 months (HR:0.8, p = 0.5) were associated with lower rates of ISUP GG upgrading. CONCLUSION: PNBs status is associated with lower rates of ISUP GG upgrading during AS for PCa. The number of PNBs and time from last PNB to PCa diagnosis (≤ 18 months) appear also to be critical for patient selection.
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a prostatická intraepiteliální neoplazie $7 D019048
- 650 12
- $a nádory prostaty $x diagnóza $x patologie $7 D011471
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a pozorné vyčkávání $7 D057832
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Luzzago, Stefano $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Marvaso, Giulia $u Department of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Laukhtina, Ekaterina $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Miura, Noriyoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Ehime University Graduate School of Medicine, Ehime, Japan
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Colombo, Alberto $u Division of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy
- 700 1_
- $a Ferro, Matteo $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy
- 700 1_
- $a Mistretta, Francesco A $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Fusco, Nicola $u Department of Pathology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Petralia, Giuseppe $u Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Jereczek-Fossa, Barbara A $u Department of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Research Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u European Association of Urology Research Foundation, Arnhem, Netherlands
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada
- 700 1_
- $a de Cobelli, Ottavio $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 700 1_
- $a Musi, Gennaro $u Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy $u Department of Oncology and Haemato-Oncology, Università Degli Studi Di Milano, 20122, Milan, Italy
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 40, č. 6 (2022), s. 1447-1454
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35347414 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134648 $b ABA008
- 999 __
- $a ok $b bmc $g 1822060 $s 1169522
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 40 $c 6 $d 1447-1454 $e 20220326 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20220720
